Literature DB >> 10022749

Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.

L Bathum1, I Johansson, M Ingelman-Sundberg, M Hørder, K Brøsen.   

Abstract

CYP2D6 is a polymorphically expressed enzyme with two phenotypes. Poor metabolizers lack the enzyme caused by inactivating mutations in the CYP2D6 gene and extensive metabolizers have at least one active CYP2D6 gene. Extensive metabolizers with very high capacity for CYP2D6 dependent drug metabolisms are termed ultrarapid metabolizers and carry alleles with duplicated, multi duplicated or amplified CYP2D6 genes. In the present study, we examined the frequency of CYP2D6 gene duplications in a Danish population and validated a long polymerase chain reaction method for identification of ultrarapid metabolizers. Sixty individuals having a metabolic ratio for sparteine at or below 0.15 were selected and a control group of 53 individuals with a metabolic ratio between 0.16 and 12.4 was used. Based on EcoRI restriction fragment length polymorphism analysis, eight individuals were found with a duplicated CYP2D6 gene, whereas using a long polymerase chain reaction method, nine individuals with a 3.6 kb fragment indicative of two CYP2D6 genes in tandem were found among the 60 individuals with a low metabolic ratio. No gene duplication was found in the control group or in any individuals with a metabolic ratio > 0.14. Based on these results, we estimate the frequency of individuals with CYP2D6 duplication in the Danish population to be 0.8%, which is comparable to the frequency in the Swedish and the German populations, but considerably lower than in Spanish or African populations. We conclude that the long polymerase chain reaction assay is simple and reliable for detection of duplications of the CYP2D6 gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10022749

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  14 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Genetic polymorphisms, drug metabolism and drug concentrations.

Authors:  Gillian M Shenfield
Journal:  Clin Biochem Rev       Date:  2004

Review 3.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 4.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.

Authors:  Jónrit Halling; Maria S Petersen; Per Damkier; Flemming Nielsen; Philippe Grandjean; Pál Weihe; Stefan Lundgren; Mia Sandberg Lundblad; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2005-07-16       Impact factor: 2.953

6.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

7.  Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.

Authors:  Tohru Ohnuma; Nobuto Shibata; Yoichiro Matsubara; Heii Arai
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 8.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.